Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Take a tour of our journey into Retinal Health through this interactive infographic or descriptive audio recording, and learn how we aim to preserve or restore vision in people with retinal diseases.
Stefan Walke, Global Head of Alliance Management, dzieli się swoimi spostrzeżeniami dotyczącymi zarządzania aliansami i jego wkładem w rozwój udanych i długotrwałych partnerstw.
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®, Aftobov® Oleosa) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.